Cod-DcDA

An exploratory study of the palliative effect of Codonopsis lanceolata on symptoms such as decreased appetite, nausea and vomiting and fatigue in patients with advanced cancer. - Cod-DcDA

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041250035

Enrollment

Registered

2025-05-23

Start date

2025-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced cancer advanced cancer

Interventions

Codonopsis lanceolata 2g/day x 28 days

Codonopsis lanceolata

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients 18 years of age or older with advanced cancer undergoing chemotherapy, receiving palliative care, or being treated in a hospice. 2) Patients who have given their free written consent to participate in this study after obtaining full informed consent. 3) Patients with an ECOG-PS of 0 to 2 4) Patients without severe allergic diseases (including severe asthma, urticaria, angioedema, chronic allergic rhinitis of long standing, etc.) 5) Patients who are expected to survive for at least 3 months 6) Patients who are able to eat and drink on their own (patients who do not require assistance or support)

Exclusion criteria

Exclusion criteria: 1) Patients who are unable to perform swallowing exercises. 2) Patients with cancer who have a treatment plan other than chemotherapy (surgery, radiotherapy, etc.) from 28 days prior to the start of this study to the end of the study. 3) Patients who are judged by the principal investigator or subinvestigator to be inappropriate to participate in this study.

Design outcomes

Primary

Measure	Time frame
Appetite suppression effect	—

Secondary

Measure	Time frame
1) Inhibition of appetite loss at Day 15 in patients with advanced cancer for whom the study subjects are receiving chemotherapy. 2) Inhibition of appetite loss at Day 15 and Day 22 in patients receiving palliative care or being treated in a hospice. 3) Nausea and vomiting at Day15 and Day22 4) Malaise at Day15 and Day22 5) Percentage increase or decrease in food intake compared to Baseline 6) Percentage change in skin blood flow (improvement in blood flow) if study subjects are advanced cancer patients receiving chemotherapy 7) Bowel movements (improvement in frequency of bowel movements, etc.) 8) Occurrence of nausea and vomiting 24-120 hours after completion of chemotherapy, use of antiemetic drugs (rescue drugs)	—

Measure

Time frame

1) Inhibition of appetite loss at Day 15 in patients with advanced cancer for whom the study subjects are receiving chemotherapy. 2) Inhibition of appetite loss at Day 15 and Day 22 in patients receiving palliative care or being treated in a hospice. 3) Nausea and vomiting at Day15 and Day22 4) Malaise at Day15 and Day22 5) Percentage increase or decrease in food intake compared to Baseline 6) Percentage change in skin blood flow (improvement in blood flow) if study subjects are advanced cancer patients receiving chemotherapy 7) Bowel movements (improvement in frequency of bowel movements, etc.) 8) Occurrence of nausea and vomiting 24-120 hours after completion of chemotherapy, use of antiemetic drugs (rescue drugs)

—

Contacts

Public ContactYasuhito Imai

Mie University Hospital

imaiya@med.mie-u.ac.jp+81-592315246

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026